Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine

Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to evaluate antibody responses in individuals vaccina...

Descripción completa

Detalles Bibliográficos
Autores principales: Chansaenroj, Jira, Suntronwong, Nungruthai, Kanokudom, Sitthichai, Assawakosri, Suvichada, Yorsaeng, Ritthideach, Vichaiwattana, Preeyaporn, Klinfueng, Sirapa, Wongsrisang, Lakana, Srimuan, Donchida, Thatsanatorn, Thaksaporn, Thongmee, Thanunrat, Auphimai, Chompoonut, Nilyanimit, Pornjarim, Wanlapakorn, Nasamon, Sudhinaraset, Natthinee, Poovorawan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317843/
https://www.ncbi.nlm.nih.gov/pubmed/35891235
http://dx.doi.org/10.3390/vaccines10071071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317843/
https://www.ncbi.nlm.nih.gov/pubmed/35891235
http://dx.doi.org/10.3390/vaccines10071071

Ejemplares similares